CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING

EHA Library, Marta Garrote Ordeig, 385504

COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY

EHA Library, Yeong Lim, 385545

MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

EHA Library, Catherine Thieblemont, 385543

A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA

EHA Library, Paolo Strati, 385542

CLINICAL IMPLICATIONS OF T CELL SUBSET COMPOSITION DURING MAINTENANCE THERAPY  AFTER FIRST-LINE IMMUNOCHEMOTHERAPY CONTAINING BENDAMUSTINE IN PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Rosalia Malafronte, 385541

CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

EHA Library, Michael Gulrajani, 385456

SPLENOMEGALY DEVELOPMENT PRECEDES THE PROGRESS OF HEMATOPOIETIC STEM CELLS MIGRATION TO SPLEEN IN MURINE MYELOFIBROSIS MODELS

EHA Library, Takaaki Maekawa, 385457

THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING

EHA Library, Nicolas Chatain, 385458

SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION

EHA Library, Ailin Zhao, 385459

PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS HAVE INCREASED NUMBERS OF MYELOID-DERIVED SUPPRESSOR CELLS, AND DECITABINE MAY HAVE A SIGNIFICANT THERAPEUTIC EFFECT IN MPN PATIENTS WITH HIGH MDSCS

EHA Library, Jian Huang, 385460

NOVEL 12-COLOR FCM + NGS STRATEGY FOR THE ACCURATE DIAGNOSIS AND STRATIFICATION OF CHRONIC MYELOMONOCYTIC LEUKEMIA. EXPERIENCE FROM THE HEMATOLOGICAL DIAGNOSIS GROUP OF ALICANTE.

EHA Library, Paula Piñero, 385461

CHARACTERIZING JAK2 MUTATED AND UNMUTATED ERYTHROCYTOSIS: A CLINICAL AND GENETIC COMPARISON

EHA Library, Sang Mee Hwang, 385462

CBL MUTATION MAY BE ASSOCIATED WITH THE ONSET OF MYELOPROLIFERATIVE NEOPLASMS WITH MICROVASCULAR DISORDERS: A SINGLE-CENTRE EXPERIENCE

EHA Library, Giorgia Micucci, 385463

GERMINAL JAK2 MOLECULAR ALTERATIONS IN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS.

EHA Library, Andrea Benetti, 385464

THE EFFECT OF THERAPY ON THE COAGULATION ACTIVITY OF MICROPARTICLES IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Natalia Silina, 385465

RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS

EHA Library, Andrew Kuykendall, 385466

REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL

EHA Library, Jason Gotlib, 385467

UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS

EHA Library, Marina Kremyanskaya, 385468

SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034

EHA Library, Haris Ali, 385470

JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE INTOLERANT TO RUXOLITINIB: AN OPEN-LABEL, SINGLE-ARM PHASE 2B STUDY

EHA Library, Yi Zhang, 385471

PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR-LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER-104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS

EHA Library, Prithviraj Bose, 385472

AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP

EHA Library, Jason Gotlib, 385473

MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Richard Schlenk, 385474

A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.

EHA Library, Prithviraj Bose, 385475

UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS

EHA Library, Claire Harrison, 385477

MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)

EHA Library, Francesca Palandri, 385478

JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN

EHA Library, Jeremy Grevet, 385479

PRELIMINARY DATA FROM THE PHASE 1/2 STUDY OF TP-3654, AN INVESTIGATIONAL SELECTIVE PIM1 KINASE INHIBITOR, SHOWED CYTOKINE REDUCTION AND CLINICAL RESPONSES IN RELAPSED/REFRACTORY MYELOFIBROSIS

EHA Library, Firas El Chaer, 385481

CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL

EHA Library, Ruben Mesa, 385482

JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE REFRACTORY OR RELAPSED TO RUXOLITINIB: A SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY

EHA Library, Yi Zhang, 385483

FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

EHA Library, Heinz Gisslinger, 385484

RING SIDEROBLASTS <15% WAS AN INDEPENDENT RISK FACTOR FOR MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH SF3B1 MUTATION AND THROMBOCYTOSIS

EHA Library, Fuhui Li, 385485

REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Johannes Lübke, 385486

TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)

EHA Library, Michael Loschi, 385488

LOW DOSE CYTARABINE FOR ADULT PATIENTS WITH NEWLY DIAGNOSED LANGERHANS CELL HISTIOCYTOSIS: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY

EHA Library, Long Chang, 385489

FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS

EHA Library, Gopila Gupta, 385490

LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT

EHA Library, Tiziano Barbui, 385491

COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY

EHA Library, Sung-Eun Lee, 385492

EFFICACY AND SAFETY OF TRAMETINIB IN ADULTS WITH LANGERHANS CELL HISTIOCYTOSIS AND ERDHEIM-CHESTER DISEASE

EHA Library, Vitalii Latyshev, 385493

REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB

EHA Library, Claire Harrison, 385494

DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST

EHA Library, Rami S. Komrokji, 385495

TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS

EHA Library, Elisa Rumi, 385496

AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Andrea Duminuco, 385497

PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA:  RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES

EHA Library, Marina Kremyanskaya, 385498

CHARACTERISTICS AND OUTCOMES OF CARDIOVASCULAR INVOLVEMENT IN ERDHEIM-CHESTER DISEASE

EHA Library, Reema Tawfiq, 385499

NEXT GENERATION SEQUECING CONTRIBUTES TO DEFINE PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM CLINICAL PHENOTYPE

EHA Library, ALDO LEONE, 385500

CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ivan Krecak, 385501

A REAL-WORLD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Minghui Duan, 385502

NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Mirjana Cvetkovic, 385503

LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.

EHA Library, Benoit Tessoulin, 385540

BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY

EHA Library, Prithviraj Bose, 385505

NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES

EHA Library, VALENTINA SANGIORGIO, 385506

INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Lucia Masarova, 385507

CHILDHOOD-ONSET ERDHEIM-CHESTER DISEASE IN THE MOLECULAR ERA: CLINICAL PHENOTYPE AND LONG-TERM OUTCOME OF 21 PATIENTS

EHA Library, Francesco Pegoraro, 385508

REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN MYELOFIBROSIS PATIENTS WITH ANEMIA

EHA Library, John Mascarenhas, 385509

THE IMPACT OF POLYCYTHEMIA VERA ON DAILY LIVING, AND SYMPTOM AND TREATMENT PERCEPTION GAPS BETWEEN PATIENTS AND PHYSICIANS: RESULTS OF A CROSS-SECTIONAL SURVEY IN JAPAN

EHA Library, Yuka Sugimoto, 385510

CLINICAL FEATURES OF PHILADELPHIA-NEGATIVE MPN DEVELOPED IN ADOLESCENTS AND YOUNG ADULTS IN JAPAN

EHA Library, Yuka Sugimoto, 385511

A SINGLE CENTER EXPERIENCE OF DIAGNOSTICS AND TREATMENT OF RARE MYELOID/LYMPHOID NEOPLASMS WITH PDGFRB GENE REARRANGEMENT

EHA Library, Irina Nemchenko, 385513

BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 STUDY

EHA Library, Chris Yasenchak, 385514

UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Peter Borchmann, 385515

PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD  INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.

EHA Library, Michael Dickinson, 385516

ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Alex F. Herrera, 385517

UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

EHA Library, Peter Borchmann, 385518

GONADAL FUNCTION AND FERTILITY PRESERVATION IN PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA TREATED ACCORDING TO THE EURONET-PHL-C2 PROTOCOL: THE FERTILITY ADD-ON STUDY

EHA Library, Katja Drechsel, 385519

DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE

EHA Library, Paolo Corradini, 385520

COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY

EHA Library, David Bond, 385521

SIGNIFICANT PREDICTORS OF DECREASED BONE MINERAL DENSITY IN PATIENTS WITH HODGKIN'S LYMPHOMA

EHA Library, Mariya Voytko, 385522

A NEW SCORING SYSTEM TO PREDICT SURVIVAL IN ELDERLY ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS: STUDY BY TURKISH SOCIETY OF HAEMATOLOGY LYMPHOMA ACADEMY WORKING GROUP

EHA Library, Özgür Mehtap, 385523

PROGNOSIS ANALYSIS AND A NEW RISK MODEL FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED BY ANTI-PD-1: A REAL-WORLD MULTICENTER RETROSPECTIVE STUDY OF PATIENTS IN CHINA

EHA Library, Wenyan Yu, 385524

ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS

EHA Library, Alessandro Cellini, 385525

PREVALENCE OF SOMATIC GENETIC MUTATIONS IN HRS CELLS OF HODGKIN LYMPHOMA PATIENTS FROM EASTERN MEDITERRANEAN, ASSESSED WITH, CIRCULATING TUMOR DNA, DIFFERS FROM THAT FOUND IN EUROPEAN COHORTS

EHA Library, Eldad Dann, 385526

RISK OF IMPAIRED OVARIAN RESERVE AND ADVERSE PREGNANCY OUTCOMES AFTER TREATMENT FOR CHILDHOOD HODGKIN LYMPHOMA; THE DCOG LATER-VEVO STUDY.

EHA Library, Katja Drechsel, 385527

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

EHA Library, Laurie Sehn, 385528

VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.

EHA Library, clementine sarkozy, 385529

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

EHA Library, Judith Trotman, 385530

A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE

EHA Library, Annalisa Chiappella, 385531

RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA

EHA Library, Nirav N Shah, 385532

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

EHA Library, Michał Taszner, 385533

LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

EHA Library, Stephen Opat, 385534

HISTOLOGICAL TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA WITHIN 48 MONTHS (TOD48) INDICATING AN ADVERSE PROGNOSIS: EVIDENCE FROM TWO POPULATION-BASED COHORTS

EHA Library, Hong-Hui Huang, 385535

EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE

EHA Library, Takahiro Kumode, 385536

COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

EHA Library, Nicole Lamanna, 385538

ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA

EHA Library, Chang-Ju Qu, 385539

PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Alexander Fossa, 385594

KEYNOTE-667: OPEN-LABEL, PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY

EHA Library, Luciana Vinti, 387915

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

EHA Library, Martin Hutchings, 385579

FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY

EHA Library, Paolo Ghia, 386446

IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B-CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS

EHA Library, Jan Burger, 386473

FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

EHA Library, Hermann Einsele, 387800

OMS906, A MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASE-3 (MASP-3) INHIBITOR, NORMALIZES HEMOGLOBIN LEVELS IN TREATMENT-NAÏVE PNH PATIENTS: INTERIM DATA FROM A PROOF-OF-CONCEPT CLINICAL TRIAL

EHA Library, Faculty / Presenters, 391325

TARGETED THERAPY OF UNCONTROLLED ERYTHROCYTOSIS IN POLYCYTHEMIA VERA WITH THE HEPCIDIN MIMETIC, RUSFERTIDE: - BLINDED RANDOMIZED WITHDRAWAL RESULTS OF THE REVIVE STUDY

EHA Library, Faculty / Presenters, 391321

BMT-CTN 1506 (MORPHO): A RANDOMIZED TRIAL OF THE FLT3 INHIBITOR GILTERITINIB AS POST-TRANSPLANT MAINTENANCE FOR FLT3-ITD AML

EHA Library, Faculty / Presenters, 391322

CEVIDOPLENIB, A SELECTIVE INHIBITOR OF SPLEEN TYROSINE KINASE (SYK), IN PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): EFFICACY AND SAFETY IN A MULTICENTER, PLACEBO CONTROLLED PHASE 2 STUDY

EHA Library, Faculty / Presenters, 391323

ACTIVITY, TOLERABILITY, AND RESISTANCE PROFILE OF THE MENIN INHIBITOR ZIFTOMENIB IN ADULTS WITH RELAPSED/REFRACTORY NPM1- MUTATED AML

EHA Library, Faculty / Presenters, 391324

ROLE OF RED BLOOD CELL MEMBRANE-DERIVED PARTICLES ON ENDOTHELIAL DAMAGES DURING ONSET STAGE OF DELAYED HEMOLYTIC TRANSFUSION REACTION

EHA Library, Nguyen-Peyre Kim-Anh, 357163

CS585 IS A FIRST-IN-CLASS COMPOUND TARGETING THE IP RECEPTOR FOR PREVENTION OF THROMBOSIS WITHOUT INCREASED RISK OF BLEEDING

EHA Library, Michael Holinstat, 357162

ASSESSING THE COST-EFFECTIVENESS OF LONG-TERM PROPHYLAXIS STRATEGIES IN VON WILLEBRAND DISEASE

EHA Library, Songkai Yan, 357161

FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRPΑ) ANTIBODY CC-95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Paolo Strati, 357083

UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A, FULLY HUMAN BCMA-DIRECTED CAR T CELLS, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, chunrui li, 357051